Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (220)	2/28/1999 4:14:00 PM
From: WWS	Read Replies (1) \| Respond to of 805

Richard, what do they mean by "on" and "off" states, do you think? Very encouraging findings. But of course it is also a completely impractical operation in its present status on any but this small number of test cases. Six or more fetuses are needed to provide a sufficient harvest of dopaminergic cells to engraft both hemispheres. And the heterogenous origins of the fetal cells required for each xenograft certainly increase the chances of rejection, hence the cyclosporin. If (big if) the fetal cells could be replaced by autologous neural stem cells one might hope for even better results.